- Home
- STTK vs RAYA Comparison
STTK vs RAYA Comparison
Compare STTK & RAYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- RAYA
- Stock Information
- Founded
- STTK 2016
- RAYA 2019
- Country
- STTK United States
- RAYA China
- Employees
- STTK N/A
- RAYA N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- RAYA Metal Fabrications
- Sector
- STTK Health Care
- RAYA Consumer Discretionary
- Exchange
- STTK Nasdaq
- RAYA Nasdaq
- Market Cap
- STTK 36.2M
- RAYA 34.2M
- IPO Year
- STTK 2020
- RAYA 2022
- Fundamental
- Price
- STTK $0.84
- RAYA $1.45
- Analyst Decision
- STTK Hold
- RAYA
- Analyst Count
- STTK 4
- RAYA 0
- Target Price
- STTK $3.00
- RAYA N/A
- AVG Volume (30 Days)
- STTK 305.5K
- RAYA 18.5K
- Earning Date
- STTK 05-01-2025
- RAYA 01-01-0001
- Dividend Yield
- STTK N/A
- RAYA N/A
- EPS Growth
- STTK N/A
- RAYA N/A
- EPS
- STTK N/A
- RAYA N/A
- Revenue
- STTK $5,721,000.00
- RAYA $22,816,585.00
- Revenue This Year
- STTK N/A
- RAYA $64.53
- Revenue Next Year
- STTK N/A
- RAYA $9.61
- P/E Ratio
- STTK N/A
- RAYA N/A
- Revenue Growth
- STTK 245.26
- RAYA N/A
- 52 Week Low
- STTK $0.69
- RAYA $0.56
- 52 Week High
- STTK $11.76
- RAYA $1.90
- Technical
- Relative Strength Index (RSI)
- STTK 44.82
- RAYA 53.43
- Support Level
- STTK $0.73
- RAYA $1.44
- Resistance Level
- STTK $0.90
- RAYA $1.90
- Average True Range (ATR)
- STTK 0.15
- RAYA 0.15
- MACD
- STTK 0.00
- RAYA 0.02
- Stochastic Oscillator
- STTK 19.96
- RAYA 42.31
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About RAYA Erayak Power Solution Group Inc.
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from three products namely inverters, chargers, and gasoline generators. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.